FDA Considers Cuts And Initiatives For Fiscal 2014 – Hamburg
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Hamburg tells FDA’s Science Board that in the early stages, both cuts and expansions are on the table as the budget process begins in preparation for the fiscal year starting October 2013.
You may also be interested in...
FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees
Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.